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Abstract
The aim of our study was to evaluate the functional peculiarities of the respiratory system and the dynamics of IL-6 in patients
with infiltrative tuberculosis combined with chronic bronchitis.
Materials and methods. There were examined 40 patients with infiltrative tuberculosis combined with chronic bronchitis: 18
patients receiving basic therapy according to the category and 22 patients who were added glucosaminilemuramylpentapep-
tide to basic therapy. Determination of IL-6 in bronchoalveolar content was performed by ELISA analysis.
Results. The additional inclusion of glucosaminilemuramylpentapeptide into the complex therapy of patients with infiltrative
tuberculosis combined with chronic bronchitis in acute phase manifests itself with positively aimed dynamic changes of
the bronchial mucous membrane according to the data of endoscopy. The standard scheme of treatment combined with
immune modulator affects the recovery of lung function in comorbidity of pathologies explaining it as the action of the means
aimed at enhancing of sanogenetic mechanisms of liquidation of combination of specific and nonspecific inflammation in the
broncho-pulmonary system, and thus – the reduction of the basis for secondary bronchial obstruction. The results of this
study indicate the advisability of administration of immune modulator of muramylpeptide series.
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Problem statement and analysis of the
recent research
According to the literature data, about 10% of people already
infected with Mycobacterium tuberculosis, can contract tu-
berculosis [1, 3, 9, 10]. Vital activity of Mycobacterium
Tuberculosis, in other cases, is controlled by the immune sys-
tem and this pathogen can be in alveolar macrophages or in
the lymph nodes [4-6, 8]. According to the data of leading
scientists, in this category of population, due to weakening of
the immune system, the disease develops in the reactivation
of latent tuberculosis infection [1, 4, 9].
According to medical literature chronic bronchitis is at
one of the first places among prevalence in patients with res-
piratory diseases, namely among chronic nonspecific diseases.
According to the statistics, the figure of the above-mentioned
morbidity has decreased only at 6%, and this is because of the
low level of complaints to doctors of such patients.
As a result of deformation and violation of bronchial
trophism, drainage deterioration of their function, which is
a favorable basis for the breeding of pathogens and fibrotic
changes in the lungs, chronic nonspecific diseases of respi-
ratory organs develop. In combination of pathologies due
to inflammatory cell activation, hypoxia of lung tissue is ob-
served. Feshchenko Yu.I. (2012) described that these viola-
tions lead to the so-called oxide stress and changes in levels
of inflammatory mediators. According to some native au-
thors, acute phase proteins manifest the greatest expression of
inflammation among biomarkers [2].
Leading scientists’ works have proved that the develop-
ment and course of tuberculosis depends on the state of the
immune system [2, 4-7, 9]. Cytomorphological and functional
immunity disorders, leading to slower processes of regression
of pathological changes in the lung tissue occur in patients
with pulmonary tuberculosis [5, 6, 11]. Tissue hypoxia that
occurs in patients with tuberculosis, leads to fibrous sclerotic
changes in the lungs [11].
Objective: To determine the effect of glucosaminilemu-
ramylpentapeptide on the state of bronchial mucous mem-
brane, external respiratory function and the level of IL-6 in
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bronchoalveolar content in patients with infiltrative tuberculo-
sis combined with chronic bronchitis.
1. Materials and methods
The study of the efficiency of the use of immune modulator
glucosaminilemuramylpentapeptide (Liasten, “Enzym” Vin-
nytsia, Ukraine) in patients with infiltrative tuberculosis com-
bined with chronic bronchitis was performed. Verification
of the diagnosis of infiltrative tuberculosis and its formula-
tion was carried out according to the materials of the Order
of MOH Ukraine # 620 from 04.09.2014 – On approval of
unified clinical protocols of primary, secondary (specialized)
and tertiary (highly specialized) medical care “Tuberculosis”.
The diagnosis of chronic bronchitis was made according to
the International Statistical Classification of Diseases and
Related Health Problems, clinical and physical-instrumental
signs (productive cough for at least 3 months a year for 2
years or more, the presence of the vesicular breathing with
dry rale in the acute phase, in medical history 2-3 exacerba-
tions per year over the past 2 years, roentgenological signs
of the walls thickening of the bronchi and the phenomena of
pneumosclerosis). There were examined 40 patients with infil-
trative tuberculosis combined with chronic bronchitis: group
I (comparison) – 18 patients receiving basic therapy accord-
ing to category (according to the Order of MOH Ukraine
#620 from 09/04/2014); group II (basic) – 22 patients who
were added glucosaminilemuramylpentapeptide to basic treat-
ment. Standard therapy of pulmonary tuberculosis consisted
of isoniaside, rifampicine, ethambutol and pyrazinamide, the
doses of which were calculated according to the weight of the
patient. Patients with chronic bronchitis were administered
anti-inflammatory, mucolytic and bronchodilator therapy. The
control group consisted of 15 practically healthy individuals
(PHI) without signs of pulmonary diseases and other diseases
of internal organs.
The first course of treatment – glucosaminilemuramylpen-
tapeptide was received intramuscularly at a dose of 2 mg,
5 injections with an interval of 5 days between them; in 3
months – the second course lasting 20 days, 1 tablet 2 mg 2
times a day.
All patients in the process of study, a number of pathogenic
features of the combination of infiltrative tuberculosis and
chronic bronchitis spirometry using spirograph “Spirokom”
was performed, and some patients (27 patients), by agreement,
were performed FBS using fibrobronchoscope of the company
“Olympus BF-20” with simultaneous taking of bronchoalve-
olar content and evaluation of inflammatory changes of the
tracheobronchial tree.
Determination of IL-6 in bronchoalveolar content (BAC)
was performed using reagents “Interleukin-ELISA-Best”.
These parameters were evaluated using the method of
enzyme immunoassay in analyzer “StatFax 303 Plus”. To
determine the content of interleukins the micro-ELISA se-
cretion assay method with the use of horseradish peroxidase
as an indicator enzyme was performed. One type of anti-
bodies was immobilized at the inner surface of plates’ pits
for microtitering. The second type of monoclonal antibodies
to epitope of the studied interleukin molecules was in com-
plexes as conjugate with biotin. Indicating component was
horseradish peroxidase conjugate with streptavidin, which has
very high affinity to biotin. After incubation and washing per-
oxidase conjugate with streptavidin was introduced into the
pits for further incubation, and then – washing, introduction
of substrate and measuring of bound peroxidase. Titration
of bronchoalveolar content was performed according to the
amount of total protein.
2. Results
In order to assess the effectiveness of glucosaminilemuramylpen-
tapeptide and standard therapy we have analyzed data of FBS
in 11 patients of group I and in 16 patients of group II.
Analysis of the data determined on the 30th day of the
performed standard treatment in patients of group I that a pro-
nounced catarrhal inflammation has decreased compared with
the index before treatment and amounted to 63.64% (p<0.05),
mild catarrhal inflammation was observed in 18.18% (p<0.05).
At the 150th day (9 patients) the phenomena of the pronounced
catarrhal inflammation decreased 2.9 times, and respectively,
mild catarrhal inflammation was observed only in 55.56% of
patients (p<0.05). Identification signs of bronchial mucosal
atrophy were without dynamic changes.
Figure 1. State of mucous membrane of bronchi at the 30th
day of treatment of group I
Inclusion of glucosaminilemuramylpentapeptide into the
standard treatment regimen of infiltrative tuberculosis com-
bined with chronic bronchitis in acute phase allowed deter-
mine the phenomena of the pronounced catarrhal inflamma-
tion on the 30th day of treatment in 56.25%. On the 150th
day of the therapy (12 patients) there was determined a fur-
ther reduction (p<0.05) of a part of the pronounced catarrhal
form of inflammation which was observed in only 16.67%
of patients and mild catarrhal inflammation was identified in
41.67% of patients. Complete recovery of the structure of the
bronchial mucosa was observed in 33.33% of patients. No
significant changes of the identification of bronchial mucosal
atrophy in the treatment process of the studied in group II
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Figure 2. State of mucous membrane of bronchi at the
150th day of treatment of group I
were not determined.
Figure 3. State of mucous membrane of bronchi at the 30th
day of treatment of group II
Figure 4. State of mucous membrane of bronchi at the
150th day of treatment of group II
Thus, the additional inclusion of glucosaminilemuramylpen-
tapeptide into the complex therapy of patients with infiltrative
tuberculosis combined with chronic bronchitis in acute phase
manifests itself with positively aimed dynamic changes of
the bronchial mucous membrane according to the data of en-
doscopy, moreover, the best result was observed in patients
who in the complex treatment took two courses: 16 patients –
intramuscularly at a dose of 2 mg, 5 injections with an inter-
val of 5 days; in 3 months (12 patients) – the second course
lasting 20 days, 1 tablet at a dose of 2 mg 2 times a day of this
immune modulator.
In assessment of spirographic indexes in patients of group
I, a slight decrease of the main rate indicators of expiratory
function (FEV1 and FVC) was revealed, which makes it im-
possible to identify the presence of ventilatory failure in this
group of patients. However, the stricter changes of MEF25,
MEF50 and MEF75 were observed.
Thus, MEF25 was (71.45±2.91) %, which was at 17.46%
lower than the control group data (p1<0.05), MEF50 fell
to (73.04±2.23) %, and was lower than 17.01% (p1<0.05),
compared with data of PHI. There was a similar tendency in
the decline of MEF75, which was (66.38±2.16) %, that was
at 23.52% lower than data of the control group (p1<0.05).
Assessing indexes of spirogram in group I after 30 days
of treatment, we have not noted marked changes. However,
MEF25 was (73.18±2.87) %, which was 1.02 times higher
than before the treatment, MEF50 at 1.05 times and MEF75
at 1.06 times exceeded the corresponding figure. During the
150th day a slight increase of indexes was determined, namely
MEF25 was (76.6±2.4) %, which at 5.15% increased as for
the given rate before the treatment (p2<0.05), but 1.21 times
less compared to the PHI (p1<0.05). MEF50 increased to
(80.59±2.1) %, and was at 7.55% higher compared with the
data before treatment (p2<0.05), but compared with the con-
trol group this figure was at 9.91% lower (p1< 0.05). The
growth of index of MEF75 (76.84±2.03) %, was at 10.46%
higher than data before treatment (p2<0.05), but 13.06%
lower than in the group of PHI (p1<0.05).
The positive effect we have got in patients of group II,
who were used immunomodulator glucosaminilemuramylpen-
tapeptide in the complex treatment; that allowed us to note
a slight increase of indexes during the 30th day of the treat-
ment: MEF25 was (75.33±2.43) %, MEF50 - (78.61±1.82)
%, and MEF75 - (73.06±2.10) %. During the 150th day we’ve
determined further significant growth rates, namely MEF25
was (89.12±1.83) %, MEF50 - (88.58±1.55) %, and MEF75 -
(82.46±2.19) %.
Thus, the full course of the intake of glucosaminilemu-
ramylpentapeptide on a background of standard treatment
regimen led to the rise of the function of expiratory respira-
tion (FER). In patients of group II the index of MEF25 on the
150th day of treatment was 1.2 times, MEF50 – 1.1 times and
MEF75 - 1.1 times better than during the corresponding period
in the subgroup III (p3<0.05) (Table 2).
However, these options are less than the values in the
control group. After analyzing the data of spirography in the
second cohort, we have noted changes during the 150th day of
the treatment: the MEF25 in 1.05 times (p1<0.05), MEF50 - in
1.02 times (p1<0.05), and MEF75 - in 1.09 times (p1<0.05)
less compared with the indexes of PHI.
Thus, the standard scheme of treatment combined with
glucosaminilemuramylpentapeptide affects the recovery of
lung function in comorbidity of pathologies explaining it as
the action of the means aimed at enhancing of sanogenetic
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Table 1. The indicators of excretory lung function during treatment in patients with infiltrative tuberculosis depending on the
presence of chronic bronchitis, (M±m)
Indexes Groups of the studied persons
p1 p2of spirometry Practically
healthy
group I, n=18
individuals
(PHI), n=15
Before
treatment
30th day 150th day
Forced Volume Vital Capacity (FVC) % 101.2±3.25 90.62±0.73 90.59±0.60 92.36±0.42 <0.05 <0.05
Forced Expiratory Volume (FEV1), % 97.3±1.47 81.56±1.01 84.99±1.27 86.61±1.59 <0.05 <0.05
Maximum Rate of Expiration (MEF25), % 93.1±4.81 71.45±2.91 73.18±2.87 76.6±2.4 <0.05 <0.05
Maximum Rate of Expiration (MEF50), % 90.5±4.11 73.04±2.23 76.68±2.05 80.59±2.1 <0.05 <0.05
Maximum Rate of Expiration (MEF75), % 89.9±3.98 66.38±2.16 70.42±2.28 76.84±2.03 <0.05 <0.05
FEV1/FVC, % 84.2±2.47 80.69±2.34 83±2.15 88.19±1.77 <0.05 <0.05
Notes:
p1 – reliability of differences of parameters between subgroups of studied and practically healthy persons;
p2 – significant difference between the indexes before and after the treatment;
p3 – significant difference of indexes between subgroups of the study.
Table 2. The indicators of excretory lung function during treatment of patients with infiltrative tuberculosis depending on the
presence of chronic bronchitis, (M±m)
Indexes Groups of the studied persons
p1 p2 p3of spirometry Practically
healthy
group II, n=22
individuals
(PHI),
n=15
Before
treatment
30th day 150th day
Forced Volume Vital Capacity (FVC) % 101.2±3.25 90.64±0.81 91.45±0.51 92.83±0.41 <0.05 <0.05 <0.05
Forced Expiratory Volume (FEV1), % 97.3±1.47 82.63±0.9 87.89±0.77 90.6±1.08 <0.05 <0.05 <0.05
Maximum Rate of Expiration (MEF25), % 93.1±4.81 69.95±2.28 75.33±2.43 89.12±1.83 <0.05 <0.05 <0.05
Maximum Rate of Expiration (MEF50), % 90.5±4.11 75.15±2.00 78.62±1.82 88.58±1.55 <0.05 <0.05 <0.05
Maximum Rate of Expiration (MEF75), % 89.9±3.98 65.9±2.12 73.06±2.11 82.46±2.19 <0.05 <0.05 <0.05
FEV1/FVC, % 84.2±2.47 80.27±1.89 85.37±1.54 91.6±0.95 <0.05 <0.05 <0.05
Notes:
p1 – reliability of differences of parameters between subgroups of studied and practically healthy individuals;
p2 – significant difference between the indexes before and after the treatment;
p3 – significant difference of indexes between subgroups of the study.
mechanisms of liquidation of combination of specific and
nonspecific inflammation in the broncho-pulmonary system,
and thus – the reduction of the basis for secondary bronchial
obstruction.
During 30 days of the standard treatment regimen of pa-
tients of group I, the concentration of IL-6 had a small positive
dynamics (Table 3). During the treatment at the 30th day in the
group I, we have seen a slight positive impact of the standard
treatment regimen for this index, level of which has decreased
at 1.12 times and amounted (184.12±14.39) pg/ml. The best
indexes we have marked at the 150th day of the standard reg-
imen of group I, where the reduction of IL-6 in BAC was
established, namely a reduction at 1.72 times (p2<0.05) as
compared to the indexes before treatment. However, the level
of IL-6, despite the described positive dynamics, in the study
group I remained at 2.62 times higher than the indexes of the
group of PHI (p1<0.05).
It should be noted that the combined therapy with the
inclusion of glucosaminilemuramylpentapeptide was more
effective for the normalization of IL-6. According to the
30th day of the treatment, we observed (132.85±10.53) pg/ml
(p2<0.05), which was better at 27.85% for the correspond-
ing period in the group I (p3<0.05) and at 34.44% better as
compared to the indexes before treatment (p2<0.05).
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Table 3. Change of the level of IL-6 (pg/ml) in bronchoalveolar content in the course of treatment of patients with infiltrative
tuberculosis combined with chronic bronchitis, (M±m)
Indexes PHI,
n=15
group I, n=11 group II, n=16 p1 p2 p3
Before
treat-
ment
30 days
of treat-
ment
150
days of
treat-
ment
Before
treat-
ment
30 days
of treat-
ment
150
days of
treat-
ment
IL-6 45.52 205.48 184.12 119.27 202.64 132.85 68.79 <0.05 <0.05 <0.05
(pg/ml) ±4.14 ±11.6 ±14.39 ±6.96 ±15.31 ±10.53 ±8.68
Notes:
p1 – reliability of differences of parameters between subgroups of studied and practically healthy persons;
p2 – significant difference between the indexes before and after the treatment;
p3 – significant difference of indexes between subgroups of the study.
At the 150th day of treatment in group II of study, we
have noted positive dynamics of IL-6 level in BAC, which
significantly decreased (p2<0.05). The achieved effect at
42.32% exceeded the same index in study group I. However,
this index remained 1.5 times higher than the values of the
PHI group (p1<0.05).
Prospects for further research. It is advisable to develop
some effective ways to influence the pathogenic level with
comorbidity to improve the effectiveness of treatment and
quality of patients’ life with infiltrative tuberculosis combined
with chronic bronchitis.
3. Conclusions
1. The additional inclusion of glucosaminilemuramylpen-
tapeptide into the complex therapy of patients with
infiltrative tuberculosis combined with chronic bronchi-
tis in acute phase manifests itself by positively aimed
dynamic changes of the bronchial mucous membrane
according to endoscopy data, and the best result was
observed in patients who in the complex treatment took
two courses: 16 patients – intramuscularly at a dose
of 2 mg, 5 injections with an interval of 5 days; in 3
months (12 patients) – the second course lasting 20
days, 1 tablet at a dose of 2 mg 2 times a day of this
immune modulator.
2. Inclusion of glucosaminilemuramylpentapeptide into
the complex treatment of patients with infiltrative tu-
berculosis and chronic bronchitis in acute phase by
two courses provides stabilization of the respiratory
function and normalization of parameters of IL-6 in
bronchoalveolar content.
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